News

Paris, December 2nd 2021 SkinDermic is very proud to announce very good results of the SDA 001 compound in the treatment of acne. SDA 001 was evaluated on a prospective, double blind, randomized trial evaluating for 12 weeks SDA 001 versus placebo in patients harboring acne. The results showed a very significant effect in the …

SkinDermic announces very good results of the SDA 001 compound in the treatment of acne. Read More »

SkinDerm has signed an official agreement with SATT IdfInnov that represents all the public structures associated with SkinDermic  in March 2018. SkinDermic has raised funds via a “Friends&Family” investment in November 2018. SkinDermic has received business development assistance from the Public Investment Bank through the PIA.

SkinDermic has raised 800 k€  via a “Friends&Family” investment in November 2018.

SkinDermic has received business development assistance from the Public Investment Bank through the PIA.